StockNews.com began coverage on shares of Horizon Therapeutics Public (NASDAQ:HZNP – Free Report) in a report published on Thursday. The brokerage issued a buy rating on the biopharmaceutical company’s stock. Separately, TheStreet cut Horizon Therapeutics Public from a b- rating to a c+ rating in a research note on Monday, May 8th. Seven research analysts […]
Pictet Asset Management SA lessened its holdings in Horizon Therapeutics Public Limited (NASDAQ:HZNP – Free Report) by 44.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 868,045 shares of the biopharmaceutical company’s stock after selling 707,473 shares during the […]
Pictet Asset Management SA cut its stake in Horizon Therapeutics Public Limited (NASDAQ:HZNP – Free Report) by 44.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 868,045 shares of the biopharmaceutical company’s stock after selling 707,473 shares during the […]
Horizon Therapeutics Public Limited (NASDAQ:HZNP – Free Report) – Research analysts at HC Wainwright raised their Q4 2023 earnings per share (EPS) estimates for shares of Horizon Therapeutics Public in a note issued to investors on Wednesday, August 9th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will earn $1.88 per share […]
Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Free Report) has received a consensus rating of “Hold” from the seven analysts that are presently covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold rating. The average twelve-month target price among brokerages that have issued a report on the stock […]